Envision Wellness Response
04/25/2023
First, I make no statements about curing anything with my patients. The things we do in our office will assist in the reduction of pain, inflammation, numbness and increase functionality, mobility and cellular regeneration. Over the last 28 years I have dealt with many patients with the same conditions as this patient with great success, including patients with stenosis, degeneration, disc bulges, nerve damage and diabetes. I have been using red and infrared light therapy for over 15 years in my practice with great success, however, it is not an immediate result, especially with neuropathy. This was explained to the patient, and is explained to all my patients. It was even mentioned that it could take up to a year for the symptoms to reduce or resolve. This patient half heartedly tried this program for not even 30 days and expected miracles. He did not fully follow the program as described. Even ,in this event, during my conversation with him after declined following the program, I did not charge him the remaining amount nor did I turn it over for collections even though the patient signed a contract. I did not lie to the patient as he stated. He called the Anodyne company, impersonating a Doctor, to get information. You can not purchase this equipment as a general rule, without a doctors' prescription. Also, there are discounts for volume, I assume he was given a volume discount price better than mine. Either way, this patient had no intention of following the program. My assumption is after he bought it he has buyers remorse and looked for a way to get out by making incorrect allegations.
Red and infrared therapy have many benefits. There are decades of supporting documents and FDA approval for many conditions, not only neuropathy, pain management, healing and inflammation, but strokes, TBI's, macular degeneration and many more conditions. Below you will find some supporting information on Anodyne alone. It was FDA cleared over 25 years ago and there are more that 11 publications to its effectiveness. This shows the effectiveness of the device and dispells the above patients statements of the treatment having inconsistent results. It also shows that neuropathies do benefit from the light therapy long term.
I hate that this patient did not get the results he was looking for but he did not give it time, it is not a miracle treatment. It is also not fair to make false allegations. We have MANY satisfied patients that follow directions and get results.
Anodyne infrared Therapy
Introduction & Background
Photobiomodulation (PBM) or low-level laser therapy (LLLT) is a non-invasive therapeutic approach that uses low-level light sources, typically in the form of low-power lasers or light-emitting diodes (LEDs), to stimulate cellular responses and promote healing. The process involves the absorption of red or near-infrared (NIR) light by specific cellular components, mainly the mitochondria, resulting in a cascade of biological reactions that enhance cellular function and overall tissue health. Photobiomodulation (PBM) or low-level laser therapy (LLLT) was demonstrated in numerous in vitro studies to exhibit unique biological effects with a dose-dependent cellular action mechanism. Since its inception in the year 1967, more than 400 randomized, double-blinded clinical trials, some featuring placebo controls, have been published for various employments. The intricate biological mechanisms responsible for LLLT/PBM's therapeutic effects have not been entirely understood, and these mechanisms might differ among cell types and tissue conditions, such as healthy versus stressed or hypoxic states. Nevertheless, both laboratory and clinical investigations indicate that LLLT/PBM effectively diminishes inflammation, prevents fibrosis, alleviates pain, and enhances overall organism function when applied appropriately.
Emerging evidence suggests that PBM primarily acts on Cytochrome c Oxidase (CcO) in the mitochondrial respiratory chain, facilitating electron transport and subsequently increasing adenosine triphosphate (ATP) production by boosting the transmembrane proton gradient [13]. As ATP is the universal energy source for all biological activities in living cells, even a minor upsurge in ATP levels can improve bioavailability for cellular metabolism functions. Furthermore, red or NIR light absorption may cause a brief, transient surge of reactive oxygen species (ROS), followed by an adaptive decrease in oxidative stress. The low ROS concentrations activate numerous cellular processes, including transcription factors such as nuclear factor kappa B (NF-?B), which in turn upregulate stimulatory and protective genes. These genes produce fibroblast growth factors, cytokines and chemokines involved in tissue regeneration.
In hypoxic cells or stressed cells, mitochondria generate nitric oxide (NO), that binds to CcO and displaces oxygen. The result of this binding leads to inhibited cellular respiration, reduced ATP generation and increased oxidative stress. This state activates various intracellular signaling pathways and transcription factors such as redox factor-1, hypoxia-inducible factor (HIF)-1, and HIF-like factor 17, activator protein-1, nuclear factor-kB, p53, activating transcription factor/cyclic adenosine monophosphate (cAMP)-response element-binding protein (ATF/CREB), inducing the downstream production of both inflammatory mediators like interleukins IL-1 and IL-6, tumor necrosis factor-alpha, cyclooxygenase (COX)-2, and prostaglandin E2 and anti-inflammatory mediators like Transforming Growth Factor-beta and IL-10.
Evidence indicates that administering LLLT/PBM with appropriate parameters to stressed cells can dissociate NO from its competitive binding to CcO, increase ATP production, and restore the balance between pro and antioxidant mediators, reducing oxidative stress. For instance, LLLT/PBM has been demonstrated to attenuate ROS production in neutrophils and reduce ROS in an animal model of traumatic tissue injury. Additionally, PBM has been found to decrease the generation of tumor necrosis factor alpha (TNF-a) and increase IL-10, an anti-inflammatory cytokine, in a model of acute lung inflammation. Furthermore, NO's vasodilatory properties can enhance blood supply to illuminated tissue, while LLLT-mediated vascular regulation increases tissue oxygenation and immune cell trafficking. These two effects may contribute to promoting wound repair and regeneration. The analgesic effects of PBM are likely induced by additional mechanisms beyond the increased ATP/reduced oxidative stress model. PBM with a relatively high-power density can inhibit A and C neuronal pain fibers when absorbed by nociceptors, slowing neural conduction velocity, reducing compound action potential amplitude, and suppressing neurogenic inflammation. PBM has the potential to modulate almost all pathogenic mechanisms in the body (e.g., inflammation, edema, pain, fibrosis, ulceration, and neuropathy and myopathy) [1].
Anodyne
Anodyne has been used to increase circulations and reduce muscle spasm since it was the first Light therapy device to be cleared by the FDA more than 25 years ago. Diabetic neuropathy is known to be based on inflammation and hypoxia of nerve cells that are unable to receive sufficient blood flow and nutrients.
By far the vast majority of patients with diabetic neuropathy obtain relief after using Anodyne therapy. These benefits have been reported in 11 publications since 2000. Best results are obtained when patients use Anodyne consistent with a care plan established by a doctor or Physical Therapist.
Of the reported studies regarding the effectiveness of Anodyne, two student show long term benefit of continuing treatment and one of these studies was conducted at a VA hospital. .